These differences in variability may be due to the fact that different tumors from the same individual were used for both pre- or on- selumetinib treatment, and these tumors likely have differing second hit mutations to NF1. Additionally, as seen in Supplemental Table 2 and Fig. 6B, D, there are high degrees of inter tumor variability regarding both Schwann cells and myeloid cells from the same individual. The gene discussed is NF1; the disease is neoplasm.